◆
Triple receptor action — targets GLP-1, GIP, and glucagon simultaneously for metabolic control no single-target compound reaches.

Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Metabolic
Research dose range
Standard research range
1 - 4 mg
The working range — where the metabolic cascade really engages, without pushing to the trial's outer edge.
Research focus
Triple-receptor metabolic remodeling
Observed window
24-48 weeks
Administration
Once weekly
Primary pathway
GLP-1 / GIP / Glucagon receptors
Jastreboff AM et al., N Engl J Med, 2023;389(6):514-526. For research use only.
MANFAAT PROTOKOL
◆
Triple receptor action — targets GLP-1, GIP, and glucagon simultaneously for metabolic control no single-target compound reaches.
◆
Rewrites your metabolic blueprint — fat loss, muscle preservation, and appetite regulation in one protocol.
◆
Backed by real Phase 2 trial results — up to 24.2% mean body weight reduction at 48 weeks, the highest of any obesity trial published at the time.
SAINS
Retatrutide activates three separate metabolic receptors at once — GLP-1, GIP, and glucagon. Most metabolic peptides target one. This targets all three, creating a cascade across fat metabolism, appetite signaling, and energy regulation that single-receptor compounds can't reach.
The trial data backs it up: a randomized, placebo-controlled Phase 2 trial (Jastreboff et al., NEJM, 2023) showed dose-dependent weight loss up to 24.2% at 48 weeks. Phase 3 data (TRIUMPH-4, 2025) pushed that further — 28.7% at 68 weeks, alongside an 86% reduction in liver fat at the top dose.
YANG DIHARAPKAN
Results are progressive. Trial data shows measurable metabolic changes within the first weeks of dose escalation, with the most significant body composition shifts building through 24-48 weeks of consistent treatment.
CATATAN PROTOKOL
Available in 10mg and 20mg. For research use only. Full documentation included with every order.
FAQ
It's the first triple-hormone-receptor agonist with published Phase 2 human trial data — GLP-1, GIP, and glucagon activated together, not one at a time.
Once weekly — the compound's roughly 6-day half-life is what makes that schedule work.